Anna Priebe, MD
Gynecologic Oncology · Tyler, TXNPI 1386765501
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Intuitive Surgical at 39.3% of the total. Reporting peaked in 2020 at $4,252 and has fallen 81.6% since, to $783 in 2025.
Across 117 payments — averaging $131.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Seagen Inc.$3K
- AstraZeneca$2K
- Eisai Inc.$2K
- GSK$695
- Myriad Genetic Laboratories, Inc.$419
- plus $1K from 21 others
Across 246 payments — averaging $6227.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aadi Bioscience, Inc.$828K
- Novartis$341K
- Merck$236K
- Karyopharm Therapeutics Inc.$82K
- Genmab U.S., Inc.$24K
- AstraZeneca$15K
- plus $5K from 3 others
What the payments were for
- Consulting fees$6,35341%
- Travel & lodging$3,20421%
- Food & beverage$3,29721%
- Education$2,52016%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 27 | $6,049 |
| Seagen Inc. | 6 | $3,283 |
| AstraZeneca | 7 | $1,855 |
| Eisai Inc. | 1 | $1,620 |
| GSK | 23 | $695 |
| Myriad Genetic Laboratories, Inc. | 7 | $419 |
| Tempus AI, Inc | 8 | $303 |
| Aadi Bioscience, Inc. | 2 | $189 |
| Genmab U.S., Inc. | 7 | $159 |
| Astellas Pharma US Inc | 3 | $143 |
| Regeneron Healthcare Solutions, Inc. | 5 | $132 |
| AbbVie | 2 | $94 |
| Incyte Corporation | 4 | $84 |
| Tesaro, Inc. | 1 | $51 |
| Merck | 2 | $49 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Avanos Medical | 1 | $25 |
| Bayer | 1 | $24 |
| Integra Lifesciences Corporation | 1 | $23 |
| Exelixis Inc. | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Novartis | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Cardinal Health 414 LLC | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,415
- LYNPARZA$1,713
- LENVIMA$1,620
- DAVINCI XI$1,000
- ZEJULA$125
- myRisk$119
- JEMPERLI$110
- Veozah$105
- myChoice CDx$105
How this compares
$15,373 in reported general payments places this provider in the 75th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 11 | $241,434 |
| EliquisApixaban | 28 | $19,450 |
| Letrozole | 71 | $1,161 |
| Gabapentin | 120 | $604 |
| Dexamethasone | 19 | $588 |
| Megestrol Acetate | 21 | $527 |
| Olanzapine | 46 | $404 |
| Prochlorperazine Maleate | 24 | $384 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 18 | $340 |
| Ibuprofen | 46 | $327 |
| Oxycodone Hcl | 31 | $298 |
| Ondansetron OdtOndansetron | 23 | $257 |
| Ondansetron Hcl | 25 | $251 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 29 | $245 |
| Levothyroxine Sodium | 38 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Lenvima | $1,620 | $241,43411 claims |
| PfizerEliquis | $19 | $19,45028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 135 gynecologic oncology providers in Texas.
Other gynecologic oncology in Tyler
- Heather PulaskiTyler$75K
- Robert ColemanHouston$864K
- Reagan StreetFort Worth$280K
- Joseph de la GarzaSan Antonio$234K
- Maurie MarkmanHouston$204K
- Dustin MandersDallas$171K
- Tiffany RedfernFort Worth$165K
- Antonio Santillan-GomezSan Antonio$162K
- Michael FrumovitzHouston$156K
- Eugene ToyEl Paso$138K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.